DEFA14A: BiomX Inc. Files Amended Proxy Statement to Correct Beneficial Ownership Table Ahead of Special Meeting

BiomX Inc. has filed a supplement to its definitive proxy statement to correct errors in the beneficial ownership table in advance of its Special Meeting of Stockholders on April 21, 2025.

Summary

• BiomX Inc. filed a supplement to its definitive proxy statement to correct errors in the beneficial ownership table.
• The supplement amends and restates the Principal Stockholders section of the proxy statement.
• The original proxy statement was filed on March 27, 2025, and supplemented on April 1, 2025, relating to the Special Meeting of Stockholders to be held online on April 21, 2025.
• The record date for determining stockholders entitled to vote at the Special Meeting remains March 17, 2025.
• The company is correcting inadvertent errors in the beneficial ownership table.
• The correction pertains to the disclosure on pages 11 through 43 of the Proxy Statement under the heading Principal Stockholders.
• The filing details the beneficial ownership of common stock as of March 17, 2025, by directors, named executive officers, and those owning greater than 5.0% of voting securities.
• The filing includes details of shares held by Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, Deerfield Management Company, L.P., OrbiMed Israel GP Ltd., Alyeska Master Fund, and AIGH Investment Partners, LP.
• The percentage of beneficial ownership is calculated based on 24,966,053 shares of Common Stock outstanding as of March 17, 2025.

Sentiment

Score: 7

Explanation: The document is a routine correction to a proxy statement, indicating a neutral to slightly positive sentiment as the company is addressing errors proactively. There are no indications of significant financial distress or negative events.

Positives

• The company is proactively correcting errors in its proxy statement to ensure accurate information is available to stockholders.
• The correction does not change the proposals to be voted on at the Special Meeting.

Negatives

• The need to file a supplement indicates an initial error in the proxy statement, which could raise concerns about the accuracy of other disclosures.

Risks

• Inaccurate disclosures, even if corrected, could potentially lead to legal or regulatory scrutiny.
• The correction might cause some stockholders to question the company's attention to detail.

Future Outlook

The document does not contain any specific forward-looking statements beyond the scheduling of the Special Meeting.

Industry Context

This filing is a routine update related to corporate governance and shareholder voting rights, typical for publicly traded companies before a significant shareholder meeting. It doesn't directly reflect on the competitive landscape or broader industry trends in biotechnology.

Comparison to Industry Standards

• Proxy filings and corrections are standard practice for publicly traded companies, ensuring compliance with SEC regulations and providing shareholders with accurate information.
• The level of detail provided in the beneficial ownership table is consistent with industry standards for proxy statements.
• Companies like Amgen, Gilead, and Biogen also routinely file proxy statements detailing similar information regarding their principal stockholders and executive compensation.

Stakeholder Impact

• The correction ensures that shareholders have accurate information for making informed voting decisions.
• The correction has minimal impact on employees, customers, suppliers, or creditors.

Next Steps

• Stockholders should review the corrected information and vote on the proposals at the Special Meeting on April 21, 2025.

Key Dates

Keywords

proxy statement, beneficial ownership, stockholders, special meeting, common stock, BiomX Inc.